Clinical trials: HCV Infection
HIV, Hepatitis C
Safety Study of Raltegravir in HIV/HCV Co-infected Patients
Current European AIDS Clinical Society (EACS) guidelines for the treatment of HIV infection recommend a combination antiretroviral regimen composed of two nucleoside reverse transcriptase inhibitors plus a ritonavir boosted…
- Trial name
- NCT01225705
- Testing
- raltegravir, Atazanavir/ritonavir
- Where
- 8 sites in Germany
- Sponsor
- University Hospital, Bonn
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C
The interferon-free combination regimen of paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- 3DUTCH (NCT02817594)
- Where
- 9 sites in Netherlands
- Volunteers
- 51 people
- Sponsor
- AbbVie
Renal Failure Chronic, Hepatitis C
Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant
Open label single center study for the donation of HCV positive kidneys to HCV negative recipients with interventional treatment to prevent HCV transmission upon transplantation.
- Trial name
- NCT03093740
- Testing
- Zepatier, Zepatier plus Sofosbuvir
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Hepatitis C
VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers
The purpose of this study is to evaluate the effect of telaprevir on the results of electrocardiograms in healthy volunteers. An electrocardiogram is an electric recording of the heart.
- Trial name
- NCT00973388
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Tibotec BVBA
Chronic Hepatitis C
Evaluation of RNA From the Liver Tissue Obtained in Patients With Chronic Hepatitis C (0000-123)
The purpose of this study is to evaluate the quality of the RNA and the reproducibility of gene expression profiling from liver tissue samples obtained by fine needle aspiration.
- Trial name
- NCT00828269
- Testing
- Comparator: Fine needle aspiration biopsy
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Hiv
Integrating HIV and Hepatitis C Screening in an Urban Emergency Department
This randomized controlled trial was implemented to evaluate the effect of integrating rapid Hepatitis C (HCV) testing into a pre-existing screening program for Human Immunodeficiency Virus (HIV) on HIV test acceptance and…
- Conditions
- Hepatitis C, Hiv, HIV/AIDS, HCV Coinfection
- Trial name
- NCT03252483
- Testing
- Bundled HCV/HIV Screening, HIV Screening
- Where
- United States
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- New York City Health and Hospitals Corporation
Chronic Hepatitis C Virus (HCV) Infection
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
The purpose of this study is to evaluate the effectiveness of telaprevir in combination with Peg-IFN-alfa-2a and ribavirin in stable liver transplant patients with chronic hepatitis C virus (HCV) genotype 1.
- Trial name
- REPLACE (NCT01571583)
- Testing
- Telaprevir, Pegylated interferon alfa-2a, Ribavirin
- Where
- 21 sites in Austria, Belgium and 4 more
- Volunteers
- 74 people
- Sponsor
- Janssen-Cilag International NV
Hepatitis C Virus (HCV)
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
The purpose of this study is to determine if 24 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and 12 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and Daclatasvir will be safe and…
- Trial name
- PRINCIPAL (NCT01616524)
- Testing
- Pegylated interferon lambda (pegIFNλ), Pegylated interferon alfa-2a (pegIFNα-2a), Ribavirin
- Where
- 124 sites in United States, Argentina and 17 more
- Volunteers
- 880 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C
The purpose of this study is to assess the efficacy and safety after administration of MP-424 to patients with chronic hepatitis C.
- Trial name
- NCT00621296
- Testing
- MP-424 (Telaprevir)
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis B, Hepatitis C
Epidemiology of Hepatitis B, C and Delta in Reunion Island
Viral hepatitis B, C and Δ represent a global public health problem for which France was very early mobilized. Despite this, in its foreword, the Dhumeaux report on "Management of people infected with hepatitis B or hepatitis C…
- Conditions
- Hepatitis B, Hepatitis C, Hepatitis D
- Trial name
- HEPEPID (NCT03362866)
- Volunteers
- 2,000 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Chronic Hepatitis c
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients
The hepatitis C virus is a major cause of chronic liver diseases, including cirrhosis and hepatocellular carcinoma, and infects approximately 3 % of the world population (150-170 million).
- Trial name
- NCT03687229
- Testing
- A)microribonucleic acid-122(miRNA-122), B) Hepatitis C virus Real Time Polymerase chain Reaction (HCV RT-PCR), A)fasting serum glucose, B)Fasting serum insulin
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assiut University
Chronic Hepatitis c
Long Term Follow up of Chronic HCV Patients Receiving DAAS
Follow up of Chronic hepatitis C Patients with moderate to severe fibrosis and cirrhosis treated with Direct Acting Antivirals after Sustained Virological Response for 4-5 years to detect changes in hepatic fibrosis and liver…
- Trial name
- NCT05170490
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Chronic Hepatitis C
Ribavirin Dose Optimization for the Treatment of Hepatitis C
Patients for whom treatment with peginterferon plus ribavirin was unsuccessful represent a category of patients for whom there is currently no worthwhile therapeutic alternative.
- Trial name
- NCT01289496
- Testing
- Peg-interferon alpha-2a, Ribavirin
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Chronic Hepatitis C
4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C
The purpose of this study is to determine if taking nitazoxanide alone for 4 weeks followed by 36 weeks of nitazoxanide plus peginterferon is superior to peginterferon plus ribavirin (standard of care) for 48 weeks.
- Trial name
- NCT00763568
- Testing
- Nitazoxanide, Peginterferon alfa-2a
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Romark Laboratories L.C.
Hepatitis C
Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin
Part A: The purpose of this study is to evaluate the safety and tolerability of INX-08189 and placebo with Peginterferon alfa-2a and Ribavirin during 12 weeks of treatment Part B: The purpose of this study is to evaluate the…
- Trial name
- NCT01425970
- Testing
- INX-08189, Pegylated interferon alfa-2a, Ribavirin
- Where
- 6 sites in United States
- Volunteers
- 210 people
- Sponsor
- Bristol-Myers Squibb
Liver Transplant; Complications, Hepatitis C
Hepatitis C Positive Organ to Recipient Hepatitis C Negative Longitudinal Transplant Study
Compare wait list mortality and time to liver, heart or kidney transplant for registrants listed to consider allografts from Hepatitis C Virus (HCV) Nucleic Amplification Testing (NAT)+ donors versus those who are not .
- Trial name
- HERCULES (NCT04057001)
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Yale University
Hepatitis C, Chronic, Drug Use
Eliminating HCV Infection Among PWUD
Identify 300 PWUD with chronic, viremic HCV infection and engage them in a multidisciplinary, generalizable model of care and initiate HCV treatment
- Trial name
- NCT05474781
- Testing
- Epclusa
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- Vancouver Infectious Diseases Centre
Hepatitis C Virus Infection
Screening, Treatment, and Eradication of Hep C
The aim of this study is to assess the HCV screening rate in Arizona by identification of potential HCV patients/subjects through different methods of communication - text message, email, social media, radio, newspaper ads, and…
- Trial name
- NCT05071261
- Testing
- Hepatitis C Virus Screening
- Volunteers
- 112,136 people, healthy volunteers welcome
- Sponsor
- Liver Institute PLLC
Hepatitis C, Chronic
ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections
Purpose of this study is to evaluate the safety, tolerability, antiviral activity, and pharmacokinetic behavior of ISIS 14803 administered for up to 12 weeks by intravenous infusions in patients with chronic hepatitis C.
- Trial name
- NCT00035945
- Testing
- ISIS 14803
- Where
- United States
- Sponsor
- Ionis Pharmaceuticals, Inc.
HIV Infections, Hepatitis C Virus
Pilot Study to Assess Gut Mucosal B Cells in Individuals With HCV and HIV
This pilot study aims to study gut B cells in HCV+HIV+, HCV+HIV-, HCV-HIV+, and HCV-HIV- volunteers. Volunteers will undergo a screening blood draw and flexible sigmoidoscopy with biopsy.
- Trial name
- NCT01040039
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Rockefeller University